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Angiogenesis plays a crucial role in the development, growth and spread of solid tumours. Pro- and anti-angiogenic factors are
abnormally expressed in tumours, inﬂuencing tumour angiogenesis, growth and progression. Polymorphisms in genes encoding
angiogenic factors or their receptors may alter protein expression and/or activity. This article reviews the literature to
determine the possible role of angiogenesis-related polymorphisms in cancer. Further research studies in this potentially crucial
area of tumour biology are proposed.
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TUMOUR ANGIOGENESIS
Angiogenesis is a complex cascade of events involving extensive
interplay between cells, soluble factors and extra-cellular matrix
components. Soluble factors including cytokines have a stimulatory
or inhibitory role, thereby regulating the process. The angiogenic
potential of tumours was initially demonstrated in animal models
and it is now recognised that angiogenesis not only precedes
tumour growth, but is also necessary for metastasis. In the normal
adult vasculature, a balance of the positive and negative angiogenic
signals maintains quiescence. However, in the tumour microenvir-
onment, angiogenesis occurs as there is either a preponderance of
pro-angiogenic molecules or a decrease in anti-angiogenic stimuli.
GENETIC POLYMORPHISMS IN ANGIOGENIC GENES
AND RELEVANCE TO CANCER CARE
Polymorphisms are naturally occurring DNA sequence variations,
which differ from gene mutations in that they occur in the
‘normal’ healthy population and have a frequency of at least 1%.
Approximately 90% of DNA polymorphisms are single nucleotide
polymorphisms (SNPs) due to single base substitutions. Others
include insertion/deletion polymorphisms, minisatellite and micro-
satellite polymorphisms. Although most polymorphisms are
functionally neutral, some have effects on regulation of gene
expression or on the function of the coded protein. These func-
tional polymorphisms, despite being of low penetrance, could
contribute to the differences between individuals in susceptibility
to and severity of disease. Certain polymorphisms alone, in combi-
nation or by interaction with environmental factors may affect the
angiogenic pathway and thereby susceptibility and/or severity of
cancers. Detection of the role of angiogenic gene polymorphisms
that inﬂuence cancer susceptibility and/or severity may improve
our understanding of tumour angiogenesis and may inﬂuence risk
stratiﬁcation and detection, use of new treatment strategies and
prognostication of disease. The efﬁcacy of anti-angiogenic treat-
ment in solid cancer (Jain, 2001) could be further enhanced, if
the individual angiogenic potential could be predicted on the basis
of genotype.
The article reviews the role of polymorphisms in genes encoding
factors and receptors that inﬂuence tumour angiogenesis. Whilst
numerous polymorphisms have been identiﬁed, we have conﬁned
this review to those that are thought to be functionally important
and may inﬂuence angiogenesis. Table 1 summarises the popula-
tion studies that have evaluated a number of the genetic
polymorphisms that will be discussed. Some ‘mutations’ with
potential functional signiﬁcance have been discussed brieﬂy, as
their prevalence in the normal population is as yet unknown.
Factors/genes, which demonstrate minimal or indirect effects on
angiogenesis such as tumour suppressor genes, oncogenes,
hormones and hematopoietic factors, are not discussed in this
review.
VASCULAR ENDOTHELIAL GROWTH FACTOR
Vascular endothelial growth factor (VEGF or VEGF-A) is one of a
family of six protein isoforms expressed in different tissues includ-
ing brain, kidney, liver and spleen. VEGF stimulates proliferation,
migration and tube formation of endothelial cells in vitro and regu-
lates vascular permeability in vivo (Veikkola and Alitalo, 1999).
VEGF expression correlates with angiogenesis and prognosis in
several tumours including breast, lung and malignant mesothelio-
ma (Toi et al, 2001; Strizzi et al, 2001).
Several polymorphisms have been described within the promoter
and 5'UTR of the VEGF gene, some of which (+405 C4G,
71154G4A and –2578C4A) correlate with VEGF production.
The +405C, –1154G and –2578C alleles are associated with low
VEGF production (Watson et al, 2000; Shahbazi et al, 2002a).
Recent studies have shown that in individuals with the –1154
AA genotype, there may be a decrease in prostate cancer risk
(McCarron et al, 2002) and reduction in invasive potential of
malignant melanomas (Howell et al, 2002). This conﬁrms earlier
studies that associate reduced VEGF production with the
71154A allele.
In another study of healthy individuals, three polymorphisms (702
C4T, 936 C4T and 1612 G4A) were identiﬁed in the 3'UTR region
of the VEGF gene. The 936 T allele was associated with decreased
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Results
Rare allele
frequency Tumour Tumour
Number of
Gene Polymorphism in controls
a Cancer susceptibility severity/survival Cases Controls Reference
VEGF 71154 G4A in A allele=0.34 Prostate AA genotype reduces No association shown 238 263 (McCarron et al,
promoter cancer risk (OR=0.45; 95% 2002)
CI=0.24–0.86)
71154 G4A in A allele=0.34 Malignant No association shown VEGF 71154AA genotype 152 266 (Howell et al,
promoter melanoma associated with thinner 2002)
tumours (P=0.002)
72578 C4A in A allele=0.48 Malignant No association shown No association shown 134 266 (Howell et al,
promoter melanoma 2002)
+405 G4Ci n5 'UTR C allele-0.31 Malignant No association shown No association shown 137 241 (Howell et al,
melanoma 2002)
936 C4Ti n3 'UTR T allele=0.12 Malignant No association shown No association shown 144 238 (Howell et al,
melanoma 2002)
936 C4Ti n3 'UTR T allele=0.13 Breast cancer No association shown No association shown 862 713 (Balasubramanian
2002)
FGFR4 Glycine to Arginine Arg
388 allele=0.31 Breast cancer No association shown Reduced disease free survival for 84 123 (Bange et al,
change at position 388 Arg
388 carriers in patients with 2002)
lymph node metastases (P=0.01)
Colonic No association shown Rare allele associated with node 82 123 (Bange et al,
cancer positivity (P=0.0016) and 2002)
advanced stage (P=0.03)
EGF 61 G4Ai n5 'UTR G allele=0.44 Malignant G/G genotype associated G/G genotype associated with 135 99 (Shahbazi et al,
melanoma with increased risk increased thickness (P=0.045) 2002b)
(OR=4.9;
95% CI=2.3–10.2)
Endostatin G4A in exon 42 A allele=0.06 Prostate Rare allele increases risk No association shown 181 198 (Iughetti et al,
(Aspartic acid to cancer (OR=2.4; 2001)
Asparagine 95% CI=1.4–4.2)
A allele=0.08 Breast cancer No association shown A allele associated with 861 697 Unpublished data
invasiveness (P-0.046)
MMP-1 71607 1G/2G 1G allele=0.39 Ovarian Common allele increases Not studied 163 150 (Kanamori et al,
cancer risk (OR=2; 95% CI=1–4) 1999)
IG allele=0.39 Endometrial Common allele increases No association shown 100 150 (Nishioka et al,
cancer risk (P=0.019) 2000)
IG allele=0.25 Lung cancer 2G/2G genotype Not studied 456 451 (Zhu et al, 2001)
increases risk (OR=1.76%;
95% CI=1.3–2.4)
– Colorectal 2G/2G genotype 2G/2G genotype increases 60 164 (Ghilardi et al,
cancer increases risk (OR=2.2; risk of metastases 2001)
95% CI=1.2–4.2) (P=0.008)
– Malignant Not studied 2G allele associated with 139 No (Ye et al,
melanoma deeper tumours controls 2001)
MMP-3 71612 5A/6A 5A allele=0.48 Breast cancer 5A carriers increase risk Not studied 43 164 (Biondi et al,
(P50.05) 2000)
Colorectal No association shown Not studied 63 164 (Biondi et al,
cancer 2000)
PAI-1 7675 4G/5G 4G allele=0.42 Breast cancer No association shown No association shown 100 106 (Blasiak &
Smolarz, 2000)
– Colorectal Not studied No association shown 40 No (Smolarz et al,
cancer controls 2001)
TNF-a 7308 G4A A allele=0.18 Breast cancer Homozygous rare allele Homozygous rare allele 243 174 (Mestiri et al,
genotype increases risk genotype decreases disease-free 2001)
(RR=4.44; P=0.006) and overall survival (P50.01)
A allele=0.21 Breast cancer No association shown No association shown 711 502 Unpublished data
A allele=0.04 Several (gastric No association shown Not studied 169 92 (Jang et al,
endometrial, 2001b)
colorectal and
renal) cancers
A allele=0.12 Colorectal No association shown No association shown 140 328 (Park et al,
cancer 1998)
7238 G4A A allele=0.07 Several (gastric A allele decreases risk Not studied 169 92 (Jang et al,
endometrial, to all these cancers 2001b)
colorectal and (OR=0.25; 95%
renal) cancers CI=0.1–0.6)
A allele=0.06 Breast cancer No association shown No association shown 714 499 Unpublished data
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morphism in breast cancer, but were unable to demonstrate any
signiﬁcant association (Balasubramanian et al, 2002).
FIBROBLAST GROWTH FACTOR
The ﬁbroblast growth factor (FGF) family includes 20 polypeptide
growth factors sharing a central core of 140 amino acids (Powers
et al, 2000). Four receptors (FGFR 1 to 4) belonging to the
immunoglobulin super family have been identiﬁed. In addition
to effects on inﬂammation, repair and tissue regeneration, FGFs
also stimulate the proliferation and migration of endothelial cells,
important in the process of angiogenesis. FGFs promote tumour
cell mitosis and angiogenesis and inhibit apoptosis (Powers et
al, 2000). FGFs, along with VEGF, play a major role in tumour
angiogenesis and their inhibition represses tumour growth
(Compagni et al, 2000). To date, no activating mutations have
been documented in FGFs. However, disturbances in the regula-
tion of FGF signalling can also occur at the receptor level.
FGFRs are over expressed in many human tumours (Shingu et
al, 1998; Yoshimura et al, 1998; Giri et al, 1999). Many point
mutations of FGFRs, found in developmental defects such as
dwarﬁsms and craniosynostotic syndromes, result in ligand-inde-
pendent activation of the FGFRs (Neilson and Friesel, 1996). A
description of all these mutations is beyond the scope of this
review. However, similar mutations have also been identiﬁed in
human gastric cancer (FGFR2 gene) and colorectal cancer (FGFR3
gene) (Jang et al, 2001a). A mutation in the activation loop of the
FGFR3 kinase domain (Lysine to Glutamic acid change), leading
to constitutive activation of FGFR3, has been identiﬁed in patients
with multiple myeloma, bladder and cervical carcinomas (Hart et
al, 2000). In the FGFR4 gene, a common polymorphism (G4A)
exists in the coding region and results in an amino acid change
(glycine to arginine change) in the transmembrane domain of
the receptor. Recently, it has been shown that the FGFR4 Arg
388 allele may predispose breast and colonic cancer patients to
rapid disease progression (Bange et al, 2002). Such genetic
changes might therefore inﬂuence the process of carcinogenesis
by affecting the intracellular signal transduction cascades following
FGF stimulation.
EPIDERMAL GROWTH FACTOR
Epidermal growth factor (EGF) exerts effects on cell proliferation
and differentiation by binding to a tyrosine kinase receptor EGF
receptor (EGFR). Although EGF can have direct effects on tumour
cells, it also promotes angiogenesis, predominantly through a mito-
genic effect on endothelial cells (Dunn et al, 2000). EGF, acting
through its receptor also stimulates the production of vascular
endothelial growth factor by tumour cells (Goldman et al, 1993),
contributing further to the angiogenic response.
A polymorphism in the 5' UTR of the EGF gene (61 G4A)
appears to predispose to the development of malignant melanoma.
The G allele is associated with higher in vitro EGF production
(Shahbazi et al, 2002b).
HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR
Hepatocyte growth factor (scatter factor; HGF/SF), a heparin-
binding glycoprotein binds to a tyrosine kinase receptor, which
is the protein product of the c-met proto-oncogene. HGF-Met
signalling is involved in developmental and homeostatic processes
and also regulates neoplastic growth and progression (To and
Tsao, 1998). It stimulates endothelial cell proliferation and migra-
tion and regulates vascular endothelial cell growth factor
expression in vascular smooth muscle cells (Van Belle et al,
1998). Increased Met and HGF/SF expression occurs in many
tumours (To and Tsao, 1998) and the HGF/Met autocrine signal-
Table 1 (Continued)
Results
Rare allele
frequency Tumour Tumour
Number of
Gene Polymorphism in controls
a Cancer susceptibility severity/survival Cases Controls Reference
TNF-b NcoI RFLP in intron 1 Rare allele=0.39 Pancreatic No association shown No association with survival 64 101 (Barber et al,
cancer 1999)
Rare allele=0.30 Lung cancer TNFB1/TNFB1 protects No clear signiﬁcant differences 102 159 (Shimura et al,
against lung cancer 1994)
(RR=0.77; P=0.01)
Rare allele=0.30 Gastric cancer No association shown Homozygous rare allele genotype 152 141 (Shimura et al,
is associated with poor survival 1995)
(P50.05)
Rare allele=0.30 Breast cancer Homozygous rare allele No association shown 95 190 (Park et al,
genotype increases risk 2002)
(OR=5.3; 95%
CI=2.3–12.2)
Rare allele=0.32 Colorectal Homozygous rare allele No association shown 136 331 (Park et al,
cancer genotype increases risk 1998)
(P50.01)
IL-10 71082 G4A G allele=0.08 Cervical A allele decreases risk No association shown 77 69 (Stanczuk et al,
cancer (OR=0.28; 95% CI= 2001)
0.1–0.6)
A allele=0.46 Malignant AA genotype increases AA genotype is associated with 153 158 (Howell et al,
melanoma risk (P=0.04) advanced disease (P=0.04) 2001)
aAs reported in the respective studies.
Table 2 Summary of the review
. Angiogenic factors play an important role in tumour development and
progression
. Potentially functional gene polymorphisms have been described in many
angiogenic genes
. Functional polymorphisms may inﬂuence tumour susceptibility and/or severity
and may help in assessing risk of disease, determining prognosis and deciding the
use of speciﬁc treatment regimens
. Both large-scale population studies and functional studies of these polymorphisms
are urgently required.
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Somatic mutations of the c-met gene in patients with renal cell
carcinoma have been shown to be oncogenic (Jeffers et al, 1997).
Met is highly expressed in human gastric carcinoma cell lines,
and a mutation (germ line missense Met mutation, P1009S)
recently identiﬁed in gastric cancer displays increased and persis-
tent tyrosine phosphorylation, when treated with HGF. Activating
missense Met mutations could therefore contribute to gastric
cancer tumorigenesis (Lee et al, 2000). Further investigations are
required to determine the role of polymorphisms in the Met gene
in angiogenesis and tumorigenesis.
TRANSFORMING GROWTH FACTOR-BETA
Transforming growth factor-beta (TGF-b) is a 25-kDa protein
which binds to three membrane molecules, TGF-b receptors type
I, II and III (Koli and Keski-Oja, 1996). TGF-bs are potent regula-
tors of cellular proliferation, differentiation and morphogenesis, as
well as extra-cellular matrix formation, extra-cellular proteolysis,
and inﬂammation. Although TGF-b inhibits cell proliferation,
neoplastic cells acquire resistance to this inhibitory activity. TGF-
b induces angiogenesis (Pertovaara et al, 1994) and this, together
with effects on stromal formation and immune function, suggests
involvement in tumour progression (Gregoire and Lieubeau,
1995). In non-small cell lung cancer, TGF-b1 protein level corre-
lates with microvessel density and prognosis (Hasegawa et al,
2001).
Several polymorphisms have been identiﬁed in the TGF-b1 gene
and have been studied in ischaemic heart disease (Andreotti et al,
2002). One coding polymorphism, (T4C resulting in Leucine to
Proline change) has been associated with serum TGF-b1 levels;
individuals with CC genotype having higher levels than TT or
TC genotype (Yokota et al, 2000). Mutations have also been iden-
tiﬁed in the exons of TGF-b1 gene in breast tumour samples
(Cardillo et al, 1997a), ovarian tumours (Cardillo et al, 1997b)
and colorectal carcinomas (Cardillo and Yap, 1997). However, as
yet no correlation has been identiﬁed between these mutations
and mRNA and/or protein expression in tumours.
TGFBR2, a receptor for TGF-b lies close to or within one of the
interstitial deletions that occur in 30–50% of head and neck,
breast, and small cell lung cancers (Lucke et al, 2001). TGFBR2
gene mutations occur in colorectal and breast cancers and can
result in absent receptor expression at the cell surface and defective
TGF-b signalling pathways (Lucke et al, 2001). Potentially, these
mutations may have a signiﬁcant inﬂuence on tumour progression.
ENDOSTATIN
Endostatin is a cleavage product of the COOH-terminal domain of
collagen XVIII, which inhibits endothelial cell proliferation in vitro
and tumour angiogenesis and growth in vivo (O’Reilly et al, 1997).
Endostatin inhibits the growth of melanoma, ﬁbrosarcoma, renal
cell, mammary and ovarian cancer (Sim et al, 2000), and is
currently being assessed in clinical trials.
Several polymorphisms have been described in the Endostatin
gene (chromosome 21) (Iughetti et al, 2001). One polymorphism,
(G4A in exon 42), which results in the change of aspartic acid to
asparagine, is associated with prostate cancer susceptibility (Iughet-
ti et al, 2001). In our study of breast cancer patients, the rare allele
of this polymorphism appears to predispose to tumour invasion
(unpublished data).
MATRIX METALLOPROTEINASES
The matrix metalloproteinases (MMPs) are a family of highly
conserved zinc-dependent endopeptidases with 20 members identi-
ﬁed to date. Several MMPs have been localised to a chromosomal
region (in 11q23), which is ampliﬁed in many solid tumours
(Curran and Murray, 1999). In addition to regulating the growth
of primary and secondary tumours, MMPs promote tumour angio-
genesis and metastasis by extracellular matrix remodelling. Altered
MMP expression occurs in tumours of the oesophagus, stomach,
colorectal, pancreatic, breast, prostate, lung and ovary with levels
correlating with disease stage and possibly prognosis (Curran and
Murray, 1999). MMP activity is inﬂuenced by transcription regula-
tion, latent MMP activation, and inhibition by endogenous tissue
inhibitors of metalloproteinases (TIMPs) (Ye, 2000).
Polymorphisms in human MMP genes are associated with
susceptibility and/or progression of various benign and malignant
conditions. MMP-1, the most widely expressed metalloproteinase
degrades interstitial collagens (types I, II and III), and over expres-
sion is implicated in tumour invasion and metastasis (Ye, 2000).
An insertion/deletion polymorphism at position –1607 (1G/2G)
results in increased binding (of the 2G allele) to recombinant
Ets-1 transcription factor and increased transcriptional activity
(Rutter et al, 1998). This allele is associated with increased
MMP-1 expression in ovarian (Kanamori et al, 1999) and endome-
trial tumour samples (Nishioka et al, 2000) and found more
frequently in ovarian cancer patients than in controls (Kanamori
et al, 1999). Recent studies have shown that the 2G allele confers
an increased susceptibility to lung cancer (Zhu et al, 2001) and
predisposition to severe disease in colorectal tumours (Ghilardi et
al, 2001) and malignant melanoma (Ye et al, 2001).
MMP-3 is also over-expressed in tumour tissues. In addition to
extracellular matrix degradation, MMP3 activates gelatinase B and
collagenases and releases cell surface molecules including E-cadher-
in, which in turn promote tumour growth (Biondi et al, 2000). A
polymorphism in MMP-3 (5A/6A at position –1612 relative to the
transcription track site) has been studied extensively in vascular
disease. The 5A allele has increased promoter activity and
decreased binding to an inhibitory transcription factor (Borghaei
et al, 1999). This allele has been associated with breast cancer,
but not with colorectal cancer (Biondi et al, 2000). Further studies
are indicated due to the small size of the study.
MMP-9 (gelatinase B) is over-expressed in both breast and
colorectal cancer (Garbett et al, 1999). Of the many identiﬁed poly-
morphisms in the MMP-9 gene, two (a (CA)n microsatellite
polymorphism at position –90 and a single nucleotide polymorph-
ism at position –1562) are functionally signiﬁcant (Shimajiri et al,
1999; Zhang et al, 1999a). Studies have shown differences in the
promoter activity between different (CA)n alleles (Shimajiri et al,
1999). The T allele of the C-1562T polymorphism demonstrates
increased transcriptional activity (Ye, 2000) and is associated with
severity of coronary atherosclerosis (Zhang et al, 1999b). Another
polymorphism detected in MMP-12 (782 A4G), also over-
expressed in tumours, regulates MMP-12 expression (Jormsjo et
al, 2000).
Tissue inhibitors of matrix metalloproteinases (TIMPs) speciﬁ-
cally inhibit the active forms of the MMPs. There are four
TIMPs (TIMP1–4) encoded by genes on different chromosomes
(Apte et al, 1994). Recent research paradoxically suggests a positive
correlation between TIMP levels and poor outcome (Curran and
Murray, 1999). Three polymorphisms (7899T4A, 7915A4G
and –1296T4C) have been identiﬁed in the promoter region of
the TIMP-3 (Beranek et al, 2000), although the functional signiﬁ-
cance is as yet unknown.
PLASMINOGEN ACTIVATOR SYSTEM
Urokinase plasminogen activator (uPA) and tissue type plasmino-
gen activator (tPA)), activators of the plasminogen system are
countered by naturally occurring plasminogen activator inhibitors
(PAI). uPA belongs to a family of serine proteases and is produced
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ogenesis, ovulation, wound healing, inﬂammation, rheumatoid
arthritis and in cancer growth, angiogenesis and metastasis
(Hildenbrand et al, 1995; Rabbani, 1998). High levels of uPA,
uPA receptor (uPAR) and paradoxically PAI-1 are associated with
a poor prognosis in many human cancers (Nekarda et al, 1994;
Pedersen et al, 1994; Foekens et al, 2000). This may be due to
excess PAI-1 release facilitating re-implantation of circulating
tumour cells, as stroma formation at the metastatic site requires
the blockade of uPA-mediated degradation of the extracellular
matrix (Janicke et al, 1991).
Two polymorphisms have been identiﬁed in the uPA gene
(Conne et al, 1997). A polymorphic microsatellite marker exists
in the uPAR gene, certain alleles of which have been found in
colorectal cancer cell lines but not in healthy individuals (Koho-
nen-Corish et al, 1996). The PAI-1 gene has several polymorphic
loci including a 3' HindIII restriction fragment length polymorph-
ism, a CA(n) dinucleotide repeat in intron 3 and a 4G/5G
insertion/deletion at position –675 in the promoter. The smaller
dinucleotide repeats are associated with higher plasma PAI-1 levels
(Dawson et al, 1991) and the –675 4G allele demonstrates
increased PAI-1 activity when compared to the 5G allele (Panahloo
et al, 1995). Studies of the 4G/5G polymorphism in small numbers
of breast (Blasiak and Smolarz, 2000) and colorectal cancer patients
(Smolarz et al, 2001) have not revealed any association with cancer.
Larger studies are required to establish a role for polymorphisms in
the PAI-1 gene.
CYTOKINES
In addition to speciﬁc angiogenic factors, certain cytokines are also
involved in regulation of angiogenesis. Cytokine gene polymorph-
isms with a speciﬁc role in angiogenesis are therefore reviewed in
the following sections.
Tumour necrosis factor
TNF-a Tumour necrosis factor (TNF)-a plays a critical role in
the pathogenesis of various inﬂammatory, autoimmune and malig-
nant diseases (Bazzoni and Beutler, 1996). Initially thought to have
anti-tumour effects, TNF-a was later shown to be tumorigenic in
vivo, with high plasma TNF-a levels associated with poor disease
outcome (Warzocha et al, 1997). Stimulation of angiogenesis by
TNF-a are well recognised, with effects modulated by other angio-
genic factors (Yoshida et al, 1997).
Functional polymorphisms in the promoter region of the TNF-a
gene at position –308 and –238 are associated with increased
severity of infectious diseases, autoimmune diseases, and non-
Hodgkin’s lymphomas (Tsukasaki et al, 2001). The functional
signiﬁcance of several other TNF-a polymorphisms have recently
been reviewed in detail (Hajeer and Hutchinson, 2001). The
uncommon allele of the –308 polymorphism (TNF2) is associated
with higher constitutive and inducible levels of TNF-a (Wilson et
al, 1997). Individuals with the TNF2 homozygous genotype
demonstrate an increased predisposition to breast cancer (RR,
4.44; P=0.006). In addition, the TNF2 homozygous genotype
appears to be an independent prognostic indicator for both disease
free survival and overall survival (Mestiri et al, 2001). However,
this polymorphism does not inﬂuence colorectal cancer risk or
severity (Park et al, 1998). The –238 A allele has been reported
to be protective against cancers in general (Jang et al, 2001b),
but this needs to be conﬁrmed in larger studies. We have recently
studied both the –308 and –238 polymorphisms in 711 breast
cancer patients and 498 age and sex-matched controls, but were
unable to demonstrate any association (unpublished data). Three
additional polymorphisms located in the 5'-ﬂanking promoter/
enhancer region of the TNF-a gene at positions –1031(T4C),
7863(C4A), and –857 (C4T) are associated with TNF-a
production, all rare alleles being associated with higher levels
(Higuchi et al, 1998). The TNF-a-857T allele is associated with
adult T-cell leukaemia/lymphoma in the Japanese population
(Tsukasaki et al, 2001). The effects on angiogenesis and the
presence of many functional polymorphisms in the TNF-a gene
certainly warrant further study in neoplastic diseases.
TNF-b (Lymphotoxin-a) Structurally related to TNF-a, stimu-
lates the production of VEGF in prostate cancer cell lines (Ferrer et
al, 1998). Increased serum levels have been associated with progres-
sion in cervical cancer (Chopra et al, 1998). A NcoI RFLP exists in
the ﬁrst intron of TNFB (gene for TNF-b); the rare allele of which
(TNFB*2) is associated with reduced TNF-b production (Messer et
al, 1991). The homozygous common allele genotype (TNFB*1/
TNFB*1) seems to protect against lung cancer (Shimura et al,
1994), colorectal cancer (Park et al, 1998) and breast cancer (Park
et al, 2002). Studies on gastric cancer have also shown a prolonged
survival in patients with this genotype (Shimura et al, 1995),
whereas no association with either susceptibility or survival was
demonstrated in pancreatic cancer (Barber et al, 1999).
Interferons
Interferons (IFN) have a multitude of biological effects on growth
and immunity, including modulation of gene expression, inhibition
of viral replication, immunomodulation, decreased cell prolifera-
tion, suppression of oncogene expression and alterations in
differentiation. There are three main types: Interferon-a, Interfer-
on-b (or Type I Interferons) and Interferon-g (Type II
interferon). Several mechanisms, including inhibition of tumour
angiogenesis, mediate the anti-tumour effects (Lindner and
Borden, 1997). Interferon-a inhibits angiogenesis by down-regulat-
ing the expression of FGF-2 (Dinney et al, 1998). Interferon-b
inhibit angiogenesis, possibly by enhanced IFN-induced gene
expression and this effect is enhanced when combined with
Tamoxifen (Lindner and Borden, 1997).
Several polymorphisms have been described in the interferon-a
genes (Golovleva et al, 1996; Muldoon et al, 2001). However, as
majority of the members of the IFN-a family have widely overlap-
ping functions, mutations in any one of the several encoding genes
may only result in minor functional consequences.
Interferon-g induces expression of IFN-inducible protein 10 (IP-
10), a potent inhibitor of angiogenesis and tumour growth in vivo
(Sgadari et al, 1996).
Of the several polymorphisms described in the IFN-g gene, a CA
repeat polymorphism in the ﬁrst intron has ﬁve alleles; the
common allele (allele 2, 24 bp long) correlates signiﬁcantly with
high levels of in vitro IFN-g production (Pravica et al, 1999).
Differential binding of nuclear factors has been reported at a poly-
morphism (+4766 C4T) in the 3'UTR (Bream et al, 2000). As yet,
these have not been associated with pathologies such as cancer.
Interleukins
Some Interleukins such as IL-8, IL-12, IL-10 and IL-4 inﬂuence
tumour growth and angiogenesis by different mechanisms.
Although several polymorphisms have been described in the encod-
ing genes, only a few have been shown to be of functional
importance. One promoter IL-10 polymorphism (71082G4A)
inﬂuences IL-10 production. The G allele (71082G) is associated
with higher cytokine production (Turner et al, 1997) and may
increase cervical cancer risk (Stanczuk et al, 2001) and cutaneous
malignant melanoma (Howell et al, 2001). At one of the IL-4 poly-
morphisms (7590C4T), the –590T allele is associated with
increased promoter activity (Rosenwasser et al, 1995). This and
other polymorphisms if proven to be of functional signiﬁcance
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STUDY DESIGN AND STATISTICAL CONSIDERATIONS
Genetic polymorphisms are being increasingly evaluated for their
role in multifactorial conditions, including cancer, using popula-
tion case–control studies. Such studies offer many advantages
when compared to family studies including:
. Recruitment of large numbers of cases and controls.
. Detection of polymorphisms that confer relative risks as low as
1.5, which is not usually possible with family studies (Risch,
2000), thus allowing identiﬁcation of low penetrance susceptibil-
ity loci.
. As cancers largely affect the middle and elderly age group, family
studies like the transmission disequilibrium test and the affected
sib pair analysis involving parents and sibs of patients are difﬁ-
cult to perform, as many will be deceased.
However, choosing an ideal control set for a population study is a
difﬁcult problem, as the age, sex and ethnicity of the case and
control groups should be matched to enable appropriate conclu-
sions to be made. Studies on functional gene polymorphisms will
be more likely to yield positive results than random polymorph-
isms simply because of the greater prior probability of being
associated with disease. However, polymorphisms in coding regions
resulting in a non-conservative amino-acid substitution in
conserved regions of the genome, or in potential transcription
factor binding sites, are also studied because of their potential
functionality. Other variants, even if not functional, can be asso-
ciated with phenotype because of linkage to closely situated
functional polymorphisms. It is now recognized that speciﬁc
combinations of polymorphisms in a gene (haplotypes) might be
of greater signiﬁcance than individual polymorphisms, not only
for a more efﬁcient capture and analysis of common genetic varia-
tion (Johnson et al, 2001), but also from a functional view point
(Daly and Day, 2001).
The numbers of patients and appropriately matched controls,
needed to demonstrate a speciﬁc relative risk with adequate power
and acceptable type I error risk in a case–control study would
depend on the frequency of the polymorphism in the population.
For example, to study a polymorphism with a rare allele
frequency of 10% (expected to be associated with cancer with
an odds ratio of 1.5) with a power of 80% and type I error rate
of 0.05, 558 individuals would be required in each group. Study-
ing rare polymorphisms (55% rare allele frequency) requires
thousands of patients to prove small associations (odds ratio of
1.5 or lower), which may be of little biological interest because
of the rarity of the polymorphism in the general population. A
detailed discussion of these and related issues can be found in
several recent reviews (Daly and Day, 2001; Risch, 2000; Weinberg
and Umbach, 2000).
CONCLUSION
Angiogenesis is a multifactorial process regulated by a plethora of
factors. Alteration in protein and/or receptor expression plays an
important role in tumour angiogenesis and progression. Poly-
morphisms in the angiogenic genes/factors may in part explain
the variation in tumour angiogenesis observed between individuals.
The functional signiﬁcance of polymorphisms can be determined
by both in vivo studies and in vitro studies. Simultaneously, well-
designed, large case–control studies are necessary to establish asso-
ciations between polymorphisms and cancer, but as yet there are
few such studies.
Individual polymorphisms, even if proven to be functional, may
only contribute to (and not solely determine) the heritable varia-
tion in protein levels and/or function. Many protein molecules
acting along different carcinogenic pathways inﬂuence the develop-
ment and spread of tumours, and hence the ﬁnal outcome. It is
therefore possible that speciﬁc combinations of polymorphisms
within one or several genes will have a greater impact on the ﬁnal
phenotype than the individual polymorphisms.
We have recently established a DNA repository containing
samples of over 1800 breast cancer patients and controls; primarily
to identify gene polymorphisms in angiogenesis-related genes that
play an important role in tumour growth and progression. We
have investigated SNPs in genes including TNF-a, VEGF and
Endostatin for associations with breast cancer severity and suscept-
ibility. Functional SNPs in the TNF-a promoter (7308G4A and
–238G4A), in the 3'UTR of the VEGF gene (936C4T) (Balasu-
bramanian et al, 2002) and in exon 42 of the Endostatin gene
(G4A change) are not associated with breast cancer. However,
the Endostatin polymorphism appears to predispose to breast
tumour invasion (unpublished data).
Identiﬁcation of the role of angiogenesis related gene poly-
morphisms in the pathogenesis of speciﬁc tumours would lead to
an increased understanding of the disease process and potentially
to risk stratiﬁcation and prognostication. At the present time, poly-
morphisms in the VEGF, MMP and PA system and TNF genes
seem to be promising in the quest for markers inﬂuencing the
severity and extent of tumour angiogenesis. In parallel with the
search for functional polymorphisms in angiogenesis related genes,
epidemiological studies to detect associations of gene polymorph-
isms with disease phenotypes are desired.
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